Management of choroidal neovascularization in myopic macular degeneration

Expert Review of Ophthalmology

Volumn 3, Issue 3, 2008, Pages 311-323

  Pece, Alfredo ^a,b   Isola, Vincenzo ^a   Vitale, Lucia ^a  

^a Melegnano Hospital   (Italy)

^b Fondazione Retina   (Italy)

Author keywords

Antiangiogenic drug; Choroidal neovascularization; Intravitreal injection; Laser photocoagulation; Natural evolution; Pathological myopia; Photodynamic therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; PEGAPTANIB; PLACEBO; RANIBIZUMAB; TRIAMCINOLONE ACETATE; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; VERTEPORFIN;

CATARACT; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EYE SURGERY; FLUORESCENCE ANGIOGRAPHY; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; LASER COAGULATION; LASER SAFETY; MYOPIA; OPHTHALMOSCOPY; PATHOGENESIS; PHOTODYNAMIC THERAPY; PROGNOSIS; RETINA DETACHMENT; RETINA FOVEA; RETINA MACULA DEGENERATION; RETINA MACULA TRANSLOCATION; REVIEW; SLIT LAMP; SUBMACULAR SURGERY; SUBRETINAL NEOVASCULARIZATION; TRANSPUPILLARY THERMOTHERAPY; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VITRECTOMY;

EID: 47249109819     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.3.3.311     Document Type: Review

References (56)

1. Ghafour IM, Allan D, Foulds WS. Common causes of blindness and visual handkap in the west of Scotland. Br. J. Ophthalmol. 67, 209-213 (1983).
2. Sperdum RD, Seigel D, Roberts J, Rowland M. Prevalmce of myopia in the United States. Arch. Ophthalmol. 101, 405-407 (1983).
3. Saw SM, Katz J, Schein OD, Chew SJ, Chan TK. Epidemiology of myopia. Epidemiol. Rev. 18(2), 175-187 (1996).
4. Vongphanit J, Mitchell P, Wang JJ. Prevalence and progression of myopic retinopathy in an older population. Ophthalmology 109(4), 704-711 (2002).
5. Curtin BJ, Karlin DB. Axial length measurements and fundus changes ofthe myopic eye. Am. J. Ophthalmol. 1, 42-53 (1971).
6. Grossniklauss HE, Green WG. Pathologic findings in pathologic myopia. Retina 12, 127-133 (1992).
7. Tano.Y. Pathologic myopia: where are we now? Am. J. Ophthalmol. 134(5), 645-660 (2002).
8. Chan WM, Ohji M, Lay TY et al. Choroidal neovascularization in pathological myopia: an update in management. Br.J. Ophthalmol. 89(11), 1522-1528 (2005).
9. Kobayashi K, Mandai M, Suzuma I et al. Expression of artrogen receptor in the choroidal neavascular membranes in highly miopic eyes. Retina 22, 418-422 (2002).
10. Hampton RG, Kohen D, Bird AC et al. Visual prognosis of disciform degeneration in myopia. Ophthalmology 90, 923-926 (l983).
11. Avila MR, Weiter JJ, Jalkh AE et al. Natural history of choroidal neavascularization in degenerative myopia. Ophthalmology 91, 1573-1581 (1984).
12. Soubrane G, Coscas G. Choroidal neovascular membranes in degenerative myopia. In: Retina. Ryan SJ (Ed.). Mosby-Year Book Inc., St Louis, MO, USA, 1143-1157 (1994).
13. Hotchkiss ML, Fine SL. Pathologic myopia and choroidal neovascularization. Am. J. Ophthalmol. 91, 177-183 (1981).
14. Brancato R, Trabucchi G, Introini U et al. Indocyanine green angiography (ICGA) in pathological myopia. Eur. J. Ophthalmol. 6, 39-43 (1996).
15. Ohno-Matsui K, Morishima N, Ito M et al. Indocyanine green angiographic findings of lacquer cracks in pathological myopia. Jpn J. Ophthalmol. 42, 293-299 (1998).
16. Yoshida T, Ohno-Matsui K, Ohtake Y et al. Long-term visual prognosis of choroidal neovascularization in high myopia. A comparison between age groups. Ophthalmology 109, 712-719 (2002).
17. Yoshida T, Ohno-Matsui & Yasuzumi K et al. Myopic choroidal neovascularization. A 10-year follow-up. Ophthalmology 110, 1297-1305 (2003).
18. Tabandeh H, Flynn HW, Scott IU et al. Visual acuity outcome of patients 50 years of age and older with high myopia and untreated chomidal neovascularization. Ophthalmology 106, 2063-2067 (1999).
19. Secretan M, Kuhn D, Soubrane G, Coscas G. Long-term visual outcome of choroidal neovascularization in pathologic myopia. Natural history and laser treatment. Eur. J. Ophthalmol. 7, 307-316 (1997).
20. Hayashi Y, Ohno-Matsui K, Yoshida T et al. Characteristics of patients with a favorable natural course Of myopic choroidal neovascularization. Graefes Arch. Clin. Exp. Ophthalmol. 243(1), 13-19 (2005).
21. Kojima A, Ohno-Matsui K, Teramukai S et al. Factors associated with the development of chorioretinal atrophy around choroidal neovascularisation in pathological myopia. Graefes Arch. Clin. Exp. Ophthalmol. 242, 114-111 (2004).
22. Pece A, Brancato R, Avanza P et al. Laser photocoagulation of choroidal neovascularization in pathologic myopia: long-term results. Int. Ophthalmol. 18, 339-344 (1995).
23. Jalkh AE, Weiter JJ, Trempc CL et al. Choroidal neovascularization in degenerative myopia: role of laser photocoagulation. Ophthalmic. Surg. 18, 721-725 (1987).
24. Ruiz-Moreno JM, Montero JA. Longterm visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes. Eur. J. Ophthalmol. 12, 117-122 (2002).
25. Brancato R, Menchini U, Pece A et al. Dye laser photocoagulation of macular subretinal neovascularization in pathological myopia. A randomised study of three different wavelengths. Int. Ophthalmol. 11, 235-238 (1988).
26. Pérex Oliván S, Torrón Fernández-Blanco C. Ferrer Novella E et al. Terapia fotodinámica en neovascularización coroidea. Arch. Soc. Esp. Oftalmol. 79, 609-616 (2004).
27. Lam DSC, Chan W-M, Liu DT et al. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow-up. Br. J. Ophthalmol. 88, 1315-1319 (2004).
28. Ergun E, Heinzl H. Stur M. Prognostic factor influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia. Am. J. Ophthalmol. 138, 434-438 (2004).
29. Verteporfin in photodynamic therapy (VIP) study group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: one-years results of a randomized clinical trial - VIP report no1. Ophthalmology 108, 841-852 (2001).
30. Verteporfin Roundtable 2000 and 2001 Participants, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators, and Verteporfin in Photodynainic Therapy (VIP) Study Group Principal Investigators. Guidelines for using verteporfin (Visudyne®) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 22, 6-18 (2002).
31. Verteporfin in photodynamic therapy (VIP) study group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-years results of a randomized clinical trial - VIP report number 3. Ophthalmology 110, 667-673 (2003).
32. Pecec A, Isola V, Vadalà M et al. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia. A long term study. Retina 26(7), 746-751 (2006).
33. Montero JA. Ruiz-Moreno JM. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularization. Br. J. Ophthalmol. 87, 173-176 (2003).
34. Axer-Siegel R, Ehrlich R, Weinberger D et al. Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at treatment. Am J. Ophthahmol. 138, 602-607 (2004).
35. Brancato R, Pece A, Avanza P, Radrizzani E. Photocoagulation scar expansion after laser therapy of choroidal neovascularization in pathologic myopia. Retina 10, 239-243 (1990).
36. Cohen SY, Bulik A, Dubois L, Quentel G. Photodynamic therapy for juxtafoveal choroidal neovascularization in myopic eyes. Arch. Ophthalmol. 136, 371-374 (2003).
37. Lam DSC, Liu DTI, Fan DSP et al. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia - 1 year result of a prospective series. Eye 19, 834-840 (2005).
38. Blair MP, Apte RS, Miskala PH et al. Retrospective case series of juxtafoveal choroidal neovascularization treated with photodynamic therapy with verteporfin. Retina 24(4), 501-506 (2004).
39. Pece A, Vadalà M, Isola V, Matranga D. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study. Am. J. Ophthalmol. 143(3), 449-454 (2007).
40. Maas S, Deutman AF, Bandhoe F, Aaderkerk AL. Surgical removal of subretinal neovascular membrane. Eur. J. Ophthalmol. 5, 48-55 (1995).
41. Adelberg DA, Del Priore L, Kaplan H. Surgery for subfoveal membrane in myopia, angioid streaks, and other disorders. Retina 15, 198-205 (1995).
42. Bottoni F, Perego E, Airaghi P et al. Surgical removal of subfoveal choroidal neovascular membranes in high myopia. Graefis Arch. Clin. Exp. Ophthalmol. 237(7), 573-582 (1999).
43. Hamelin N, Glacet-Bernard A, Brindeau C, Mimoun G, Coscas G, Soubrane G. Surgical treatment of subfoveal neovascularization in myopia: macular translocation vs surgical removal. Am. J. Ophthalmol. 133(4), 530-536 (2002).
44. Au Eong KG, Pieramici DJ, Fujii GY et al. Macular translocation: unifying concepts, terminology, and classification. Am. J. Opthalmol. 131(2), 244-253 (2001).
45. Ozdek S, Hondur A, Gurelik G, Hasanreisoglu B. Transpupillary thermotherapy for myopic choroidal neovascularization: 1-year follow-up: TTT for myopic CNV. Int. Ophthalmol. 26(4-5), 127-133 (2005).
46. Marticorena J, Gomez-Ulla F, Fernandez M, Pazos B, Rodriguez-Cid MJ, Sanchez-Salorio M. Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularization. Am. J. Ophthalmol. 142(2), 335-337 (2006).
47. Chan WM, Lai TY, Wong AL, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularization secondary to pathological myopia: a pilot study. Br. J. Ophthalmol. 91, 174-179 (2007).
48. Chakravarthy U, Adamis AP, Cunningham ET Jr et al.; VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 113(9), 1508 e1-e25 (2006).
49. Bennett MD, Yee W. Pegaptanib for myopic choroidal neovascularization in a young patient. Graefe Arch. Clin. Exp. Ophthalmol. 245, 903-905 (2007).
50. Ruiz-Moreno JM, Gomez-Ulla F, Montero JA et al. Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye (2007) (Epub ahead of print).
51. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevaciziunab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 114(12), 2190-2196 (2007).
52. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathological myopia. Br. J. Ophthalmol. 91, 157-160 (2007).
53. Sakaguchi H, Ikuno Y, Gomi F et al. Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathological myopia. Br. J. Ophthalmol. 91, 161-165 (2007).
54. Hernández-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization pathologic myopia. Retina 27, 707-712 (2007).
55. Rosenfeld PJ, Brown DM, Heier JS et al.; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N. Engl J. Med. 355(14), 1419-1431 (2006).
56. Brown DM, Kaiser PK, Michels M et al.; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355(14), 1432-1444 (2006).